Success Metrics

Clinical Success Rate
72.7%

Based on 8 completed trials

Completion Rate
73%(8/11)
Active Trials
2(15%)
Results Posted
63%(5 trials)
Terminated
3(23%)

Phase Distribution

Ph phase_2
2
15%
Ph phase_1
10
77%
Ph phase_3
1
8%

Phase Distribution

10

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
10(76.9%)
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(8)
Terminated(3)

Detailed Status

Completed8
Terminated3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
72.7%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (76.9%)
Phase 22 (15.4%)
Phase 31 (7.7%)

Trials by Status

active_not_recruiting215%
completed862%
terminated323%

Recent Activity

2 active trials
Showing 5 of 13
active_not_recruitingphase_2

Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937
active_not_recruitingphase_1

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

NCT01434316
terminatedphase_1

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03484520
completedphase_1

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

NCT01676753
terminatedphase_1

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

NCT02684617
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00937937Phase 2

Dinaciclib in Treating Patients With Stage IV Melanoma

Active Not Recruiting
NCT01434316Phase 1

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Active Not Recruiting
NCT03484520Phase 1

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Terminated
NCT01676753Phase 1

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Completed
NCT02684617Phase 1

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

Terminated
NCT01711528Phase 1

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed
NCT01624441Phase 1

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Completed
NCT01515176Phase 1

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Completed
NCT01783171Phase 1

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Completed
NCT01026324Phase 1

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Terminated
NCT01580228Phase 3

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

Completed
NCT01650727Phase 1

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Completed
NCT01096342Phase 2

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13